Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33256240)

  • 1. The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future.
    Djanani A; Eller S; Öfner D; Troppmair J; Maglione M
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer.
    Lee HM; Morris V; Napolitano S; Kopetz S
    Oncology (Williston Park); 2019 Jun; 33(6):206-11. PubMed ID: 31219603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
    Grothey A; Fakih M; Tabernero J
    Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.
    Strickler JH; Wu C; Bekaii-Saab T
    Cancer Treat Rev; 2017 Nov; 60():109-119. PubMed ID: 28946014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer.
    Johnson B; Kopetz S
    Target Oncol; 2020 Oct; 15(5):567-577. PubMed ID: 32889679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Metastasectomy in the Multimodality Approach for
    Johnson B; Jin Z; Truty MJ; Smoot RL; Nagorney DM; Kendrick ML; Kipp BR; Grothey A
    Oncologist; 2018 Jan; 23(1):128-134. PubMed ID: 28904173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF in metastatic colorectal cancer: the future starts now.
    Orlandi A; Calegari A; Inno A; Berenato R; Caporale M; Niger M; Bossi I; Di Bartolomeo M; de Braud F; Pietrantonio F
    Pharmacogenomics; 2015 Dec; 16(18):2069-81. PubMed ID: 26615988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Evolving Treatment Landscape in
    Tabernero J; Ros J; Élez E
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35503983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
    Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
    Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF-Directed Therapy in Metastatic Colorectal Cancer.
    Korphaisarn K; Kopetz S
    Cancer J; 2016; 22(3):175-8. PubMed ID: 27341594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer.
    Shahjehan F; Kamatham S; Chandrasekharan C; Kasi PM
    Drugs Today (Barc); 2019 Nov; 55(11):683-693. PubMed ID: 31840683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.
    Tan L; Tran B; Tie J; Markman B; Ananda S; Tebbutt NC; Michael M; Link E; Wong SQ; Chandrashekar S; Guinto J; Ritchie D; Koldej R; Solomon BJ; McArthur GA; Hicks RJ; Gibbs P; Dawson SJ; Desai J
    Clin Cancer Res; 2023 Mar; 29(6):1017-1030. PubMed ID: 36638198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study.
    Eriksen M; Pfeiffer P; Rohrberg KS; Yde CW; Petersen LN; Poulsen LØ; Qvortrup C
    BMC Cancer; 2022 Dec; 22(1):1321. PubMed ID: 36527039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis.
    Mao C; Liao RY; Qiu LX; Wang XW; Ding H; Chen Q
    Mol Biol Rep; 2011 Apr; 38(4):2219-23. PubMed ID: 20857202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment options in BRAF-mutant metastatic colorectal cancer.
    Bernabe-Ramirez C; Patel R; Chahal J; Saif MW
    Anticancer Drugs; 2020 Jul; 31(6):545-557. PubMed ID: 32304411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined BRAF, EGFR, and MEK Inhibition in Patients with
    Corcoran RB; André T; Atreya CE; Schellens JHM; Yoshino T; Bendell JC; Hollebecque A; McRee AJ; Siena S; Middleton G; Muro K; Gordon MS; Tabernero J; Yaeger R; O'Dwyer PJ; Humblet Y; De Vos F; Jung AS; Brase JC; Jaeger S; Bettinger S; Mookerjee B; Rangwala F; Van Cutsem E
    Cancer Discov; 2018 Apr; 8(4):428-443. PubMed ID: 29431699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer.
    Yaeger R; Cercek A; Chou JF; Sylvester BE; Kemeny NE; Hechtman JF; Ladanyi M; Rosen N; Weiser MR; Capanu M; Solit DB; D'Angelica MI; Vakiani E; Saltz LB
    Cancer; 2014 Aug; 120(15):2316-24. PubMed ID: 24737664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective Analysis of Treatment Pathways in Patients With BRAF
    Gerger A; Eisterer W; Fuxius S; Bastian S; Koeberle D; Welslau M; Sanoyan DA; Maas C; Uhlig J; Fenchel K; Greil R; VON DER Heyde E; Agocs GR; Weide R; Schwager M; Reichenbach F; Modest DP; Fritsch R
    Anticancer Res; 2022 Oct; 42(10):4773-4785. PubMed ID: 36191968
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Ros J; Baraibar I; Sardo E; Mulet N; Salvà F; Argilés G; Martini G; Ciardiello D; Cuadra JL; Tabernero J; Élez E
    Ther Adv Med Oncol; 2021; 13():1758835921992974. PubMed ID: 33747149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.